Skip to main
DMRA

DMRA Stock Forecast & Price Target

DMRA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Damora Therapeutics is poised to have a significant impact in the treatment of hematologic disorders through its pipeline products DMR-001, DMR-002, and DMR-003. Based on preclinical data, DMR-001 has shown high potency and selectivity for Type 1 and Type 2 mutCALR, giving it the potential to compete in both essential thrombocythemia and myelofibrosis treatment markets. Its convenient subQ administration and Fc-null design also set it apart from other anti-mutCALR therapies in development, making it a strong player in the market.

Bears say

Damora Therapeutics is a pre-clinical stage biotechnology company with a relatively unproven pipeline of products targeting hematologic disorders. Their current market valuation of $3,191M seems high given the risks and uncertainties associated with pre-clinical and clinical development, potential competition from established and emerging therapies, and the potential for limited commercial adoption. Furthermore, the company's relatively high R&D expenses of $95.8M and $100.4M in FY2026 and FY2027, respectively, and lack of long-term investments and marketable securities may raise concerns about their financial stability and ability to execute on their ambitious goals.

DMRA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Damora Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Damora Therapeutics, Inc. (DMRA) Forecast

Analysts have given DMRA a Buy based on their latest research and market trends.

According to 5 analysts, DMRA has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $44.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $44.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Damora Therapeutics, Inc. (DMRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.